CHOP protocol-cyclophosphamide/doxorubicin/prednisone/vincristine

Known as: CTX/DOX/PRED/VCR, ACOP, cyclophosphamide, doxorubicin, prednisone, and vincristine protocol 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
BACKGROUND Present first-line therapy for diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND The MInT study was the first to show improved 3-year outcomes with the addition of rituximab to a CHOP… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND The outcome of diffuse large B-cell lymphoma has been substantially improved by the addition of the anti-CD20… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
To the Editor: Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK) tyrosine kinase, is active in non–small-cell lung… (More)
  • figure 1
Is this relevant?
Highly Cited
2007
Highly Cited
2007
PURPOSE Our previous phase II trial for treating human T-lymphotropic virus type I-associated adult T-cell leukemia-lymphoma… (More)
Is this relevant?
Highly Cited
2006
Highly Cited
2006
The purpose of this study is to compare our standard chemotherapy regimen (CHVP [cyclophosphamide, doxorubicin, teniposide, and… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
Is this relevant?
Highly Cited
2006
Highly Cited
2006
We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
PURPOSE Long-term follow-up with updated time to disease progression (TTP) and duration of response (DR) data are presented from… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
In diffuse large B-cell lymphoma (DLBCL), the combination of rituximab and CHOP (cyclophosphamide, doxorubicine, vincristine… (More)
  • figure 1
  • table 2
  • table 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
The copA gene product, a putative copper-translocating P-type ATPase, has been shown to be involved in copper resistance in… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • figure 5
Is this relevant?